BIOPROGNOS is a clinical reference company specializing in personalized blood-based testing to help find, understand, and address cancer, as well as other conditions, risk.
Thanks to cutting-edge nucleosome detection and analysis techniques, a team formed by Molina, R., R. M. Marrades, J. M. Auge, J. M. Escudero, N. Vinolas, N. Reguart, J. Ramirez, X. Filella, L. Molins and A. Agusti from the Hospital Clínic de Barcelona started testing ―about 10 years ago―, to use blood as early diagnosis tools for Lung Cancer, based on irregular levels of uniquely structured nucleosomes in body fluids, and by measuring and analyzing them, to establish whether disease is present in the patient. This research ended up with a paper published on October 2015 and titled “Assessment of a Combined Panel of Six Serum Tumor Markers for Lung Cancer”, that BIOPROGNOS licensed on January 2016 through an exclusive technology transfer agreement with Hospital Clínic de Barcelona and the Fundació Clínic per a la Recerca Biomèdica for the commercial explotation and further innovation.
Besides, BIOPROGNOS started working with other prime worldwide institutions in order to develop early diagnosis solutions for other cancer types like Ovarian, Prostate and Cancer Unknown Primary (already finished and in regulatory process to obtain CE Declaration of Conformity), as well as other ones as main focus for the company’s 2017 pipeline.
For years, biopsy and imaging have been at the forefront of cancer treatment, providing important insights about cancer, especially when it comes to detection.
But these procedures are inherently limited. The added risk and stress associated with biopsy can be hard on patients. And for those with advanced or inaccessible cancers, biopsy and imaging may not be an option. Scans may be less invasive, but do not provide critical molecular information. These procedures add significant costs over the course of treatment.
In this way, BIOPROGNOS has developed its own technology called “Multiple Biomarkers Disease Activity Algorithms” (MBDAAs) in order to create a non-invasive first-line for diagnosis.
MBDAA are intended for the qualitative detection of several neoplasia associated biomarkers body fluids.
A positive result may indicate the presence of cancer and should be followed by a other diagnostic procedures, such a CT Scan or a colonoscopy, among others. MBDAA are indicated to screen men and women 40 years or older, who are at typical average-risk for lung, breast, ovarian or prostate cancers. Both false positives and false negatives do occur. Any positive result should be followed by a diagnostic procedure. Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient.
The option to replace additional biopsies and scans with either a blood or urine test gives physicians the flexibility to create a monitoring plan that fits with virtually any patient care setting. Moreover, for patients with advanced cancers who may not be candidates for invasive diagnostic procedures, MBDAA can also provide valuable information that was previously unavailable to physicians.
BIOPROGNOS has already developed several non-invasive MBDAA for cancer screening and detection. Please browse next pages for more information about them:
- OncoBREAST Dx (MBDAA for Breast Neoplasia)
- OncoLUNG (MBDAA Dx for Lung Neoplasia)
- OncoOVARIAN Dx (MBDAA for Ovarian Neoplasia)
- OncoPROSTATE Dx (MBDAA for Prostate Neoplasia)
- OncoCUP Dx (MBDAA for Unknown Primary Neoplasia)
BIOPROGNOS’ approach to research and development and the experience of our R&D staff give us a unique advantage as we develop screening tests for new cancer, as well as other conditions, and pursue our vision: to enjoy a better health.
In this way, BIOPROGNOS is applying all the know-how aquired previously in the development of new MBDAAs for the diagnosis of Bladder, Colorectal, Liver, Pancreas, Stomach and Tyroid cancer, among others.